semapimod
Small moleculeexperimental
Semapimod (INN), formerly known as CNI-1493, is an investigational new drug which has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral and antimalarial properties. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2002 (NCT00038766)
Timeline
Indications
Studied for
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C/C(=N\NC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(/C(C)=N/NC(=N)N)cc(/C(C)=N/NC(=N)N)c2)cc(/C(C)=N/NC(=N)N)c1- Mol. weight
- 744.91 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSemapimod ↗
- ChEMBLCHEMBL2107779 ↗
Also known as
- cni 1493
- cni-1493
- cni-1493
- cni-1493
- cpsi-2364
- cpsi-2364
- n,n'-bis(3,5-bis(1-(carbamimidoylhydrazono)ethyl)phenyl)decanediamide
- semapimod
- semapimod
- semapimod
- semapimod
- semapimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00950105 | Phase 1 | Jul 1, 2009 | Ferring, IQVIA |
| NCT00741910 | Phase 2 | Jul 1, 2003 | Ferring, University of Amsterdam |
| NCT00740103 | Phase 2 | Dec 1, 2002 | Ferring, University of Amsterdam |
| NCT00739986 | Phase 2 | Oct 1, 2002 | Ferring, University of Amsterdam |
| NCT00038766 | Phase 2 | Jun 1, 2002 | Ferring, University of Amsterdam |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 5 | 5 | 2 | 2002 |
| University of Amsterdam | Academic/Hospital | 4 | 0 | 1 | 2002 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1